Integrated quality control processes for cell therapy workflows

CAR-T cell therapy research for B cell cancers must meet FDA guidelines for safety, efficacy, and stability. Accurate testing, including cytokine assays, is essential to avoid risks like cytokine-release syndrome in research settings. Development of cell and gene therapy research faces multiple bottlenecks, especially in the characterization and QC processes which are traditionally manual and time-consuming. The need for an automated solution to streamline the research workflow and minimize manual intervention is critical to improving throughput and consistency.

Read in this Application Note how to automate plate preparation of Luminex^® multiplex immunoassays, such as the Invitrogen™ ProcartaPlex™ immunoassay to significantly reduce hands-on time while standardizing workflows when measuring cytokines and other biomarkers on the Luminex xMAP^® System.

Thermo Fisher Scientific is a partner of Luminex.